Related Experiment Video
Updated: Feb 24, 2026
06:07
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.3K
Mitochondrial-Associated Membranes in Parkinson's Disease
Nobutaka Hattori1, Taku Arano2, Taku Hatano2
1Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan. nhattori@juntendo.ac.jp.
Advances in Experimental Medicine and Biology
|August 18, 2017
Summary
Parkinson's disease (PD) is a growing concern, especially with an aging population. This review explores mitochondria-associated membranes (MAM) as potential therapeutic targets for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Cell Biology
- Genetics
Background:
- Parkinson's disease (PD) is a common neurodegenerative disorder, with aging as a primary risk factor.
- The increasing lifespan worldwide predicts a rise in PD cases, necessitating disease-modifying therapies.
- Monogenic PD provides insights into pathogenesis, with mitochondrial dysfunction implicated in both monogenic and sporadic forms.
Purpose of the Study:
- To review the role of mitochondrial dysfunction in Parkinson's disease.
- To highlight mitochondria-associated membranes (MAM) as a potential common pathway in PD pathogenesis.
- To explore the therapeutic potential of targeting MAM for Parkinson's disease.
Main Methods:
- Literature review focusing on mitochondrial dysfunction in PD.
- Analysis of the role of alpha-synuclein and other gene products in MAM.
- Examination of MAM as a potential therapeutic target.
Main Results:
- Mitochondrial impairment is a likely common pathway in both monogenic and sporadic Parkinson's disease.
- Mitochondria-associated membranes (MAM) are dynamic interfaces between mitochondria and endoplasmic reticulum.
- Alpha-synuclein is a key component of MAM, suggesting its involvement in PD pathogenesis via MAM.
Conclusions:
- Mitochondria-associated membranes (MAM) represent a promising novel therapeutic target for Parkinson's disease.
- Understanding MAM's role in PD pathogenesis could lead to effective disease-modifying treatments.
- Targeting MAM may offer a unified therapeutic strategy for various forms of Parkinson's disease.
Related Concept Videos
01:45Mitochondrial Membranes
17.5K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.5K
01:28The Inner Mitochondrial Membrane
4.8K
The inner mitochondrial membrane is the primary site of ATP synthesis. The inner membrane domain that forms a smooth layer adjacent to the outer membrane is called the inner boundary membrane. This domain contains membrane transporters that drive metabolites in and out of the mitochondria. In contrast, the inner membrane network that invaginates into the matrix space is called the cristae membrane. This domain accounts for principle mitochondrial function as it accommodates the protein...
4.8K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:37Neural Regulation
43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K